Effects of omega-3 fatty acids on lipids and glycemic control in type II diabetes and the metabolic syndrome and on inflammatory bowel disease, rheumatoid arthritis, renal disease, systemic lupus erythematosus, and osteoporosis / prepared by Southern California/RAND Evidence-based Practice Center.

Format:

Book

Government document

Contributor:

Southern California Evidence-Based Practice Center/RAND

United States. Agency for Healthcare Research and Quality

Series:

Evidence report/technology assessment ; no. 89.

AHRQ publication ; no. 04-E 012-2.

Evidence report/technology assessment ; no. 89

AHRQ publication ; no. 04-E 012-2

Language:

English

Subjects (All):

Omega-3 fatty acids--Therapeutic use.

Omega-3 fatty acids.

Fatty Acids, Omega-3--therapeutic use.

Arthritis, Rheumatoid--drug therapy.

Diabetes Mellitus, Type 2--drug therapy.

Inflammatory Bowel Diseases--drug therapy.

Kidney Diseases--drug therapy.

Lupus Erythematosus, Systemic--drug therapy.

Metabolic Syndrome--drug therapy.

Osteoporosis--drug therapy.

Medical Subjects:

Fatty Acids, Omega-3--therapeutic use.

Arthritis, Rheumatoid--drug therapy.

Diabetes Mellitus, Type 2--drug therapy.

Inflammatory Bowel Diseases--drug therapy.

Kidney Diseases--drug therapy.

Lupus Erythematosus, Systemic--drug therapy.

Metabolic Syndrome--drug therapy.

Osteoporosis--drug therapy.

Physical Description:

1 online resource (x, 145 pages) : illustrations.

Place of Publication:

[Rockville, Md.] : [Agency for Healthcare Research and Quality, U.S. Dept. of Health and Human Services], [2004]

Notes:

Title from title screen (viewed Apr 13, 2004).

Includes bibliographical references.

Other Format:

Print version: Effects of omega-3 fatty acids on lipids and glycemic control in type II diabetes and the metabolic syndrome and on inflammatory bowel disease, rheumatoid arthritis, renal disease, systemic lupus erythematosus, and osteoporosis.

ISBN:

1587631415

9781587631412

OCLC:

54942859